Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

TET2 -mutant clonal hematopoiesis and risk of gout

Blood (2022) 140 (10): 1094–1103.

https://doi.org/10.1182/blood.2022015384

Published: 2022

Includes: Supplemental data

Journal Articles

The Association between Clonal Hematopoiesis and Gout

Mridul Agrawal, Abhishek Niroula, Pierre Cunin, Marie McConkey, Peter G. Kim, Waihay J. Wong, Lachelle D. Weeks, Amy E. Lin, Peter G. Miller, Christopher J. Gibson, Aswin Sekar, Donna S. Neuberg, Alexander G. Bick, Pradeep Natarajan, Peter A. Nigrovic, Deepak A. Rao, Benjamin L. Ebert

Blood (2021) 138 (Supplement 1): 595.

https://doi.org/10.1182/blood-2021-153639

Published: 2021

Journal Articles

Experimental Modeling of Acute- and Chronic-GvHD By Xenotransplanting Human Donor PBMCs or Cord Blood CD34 + Cells (HSC) into NSG Mice

Ann E Lin, PhD, Sonia Reyes, Xiaoyu An, Sonia Reyes, Wenqing Yang, PhD, Derron Yu, Duan Dan, PhD, Henry Li, PhD

Blood (2018) 132 (Supplement 1): 5684.

https://doi.org/10.1182/blood-2018-99-115462

Published: 2018

Journal Articles

Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant

Gautam Borthakur, MD, Amer Beitinjaneh, MD, E. Lin, Jorge E. Cortes, MD, Rajyalakshmi Luthra, PhD, Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Akhshar Hemantkumar Patel, Gabriela Rondon, MD, Sergio Giralt, MD, Richard Champlin, Hagop Kantarjian, MD, Marcos de Lima, MD

Blood (2010) 116 (21): 1722.

https://doi.org/10.1182/blood.V116.21.1722.1722

Published: 2010

Journal Articles

A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation

Blood (2010) 116 (21): 2358.

https://doi.org/10.1182/blood.V116.21.2358.2358

Published: 2010

Journal Articles

Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study.

Irene M Ghobrial, Jean-Luc Harousseau, Steven P Treon, Brianna Harris, Courtney E Lin, Zheng Yuan, Karim Benhadji, James E Wooldridge, Veronique Leblond

Blood (2009) 114 (22): 3867.

https://doi.org/10.1182/blood.V114.22.3867.3867

Published: 2009

Journal Articles

Outcomes of Salvage Treatment in Patients with Acute Myeloid Leukemia (AML) with FLT3 Mutations.

Yiming Chen, MD., PhD., Jorge Cortes, MD, E. Lin, Farhad Ravandi, M.D., Stefan Faderl, MD, Tapan Kadia, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2009) 114 (22): 2078.

https://doi.org/10.1182/blood.V114.22.2078.2078

Published: 2009

Journal Articles

A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.

Irene M Ghobrial, Nikhil C Munshi, Brianna N Harris, Zheng Yuan, Nichole M Porter, Robert L Schlossman, Jacob P Laubach, Kenneth C. Anderson, Courtney E Lin, James E Wooldridge, Paul G Richardson, Rafat Abonour

Blood (2009) 114 (22): 1870.

https://doi.org/10.1182/blood.V114.22.1870.1870

Published: 2009

Journal Articles

Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).

Nicolas Batty, MD, Xavier C. Badoux, MBBS, Michael Keating, MD, E. Lin, Susan Lerner, M.S., RHIA, Susan O'Brien, Alessandra Ferrajoli, MD., Tapan Kadia, MD, Jan A. Burger, MD, PhD, Stefan Faderl, MD, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 3448.

https://doi.org/10.1182/blood.V114.22.3448.3448

Published: 2009

Journal Articles

Chromosome 17 Abnormalities Are Associated with Worse Overall and Relapse Free Survival in Patients with Acute Myelogenous Leukemia and Poor-Risk Cytogenetics.

Gautam Borthakur, MD, Constantine Tam, Hagop Kantarjian, E. Lin, Jorge Cortes, Susan O’Brien, Charles Koller, Sherry Pierce, Michael Keating

Blood (2008) 112 (11): 1501.

https://doi.org/10.1182/blood.V112.11.1501.1501

Published: 2008

Journal Articles

Venothromboembolism (VTE) in Patients (pts) with Acute Lymphocytic Leukemia (ALL), Burkitt’s Leukemia/Lymphoma (BL) or Lymphoblastic Lymphoma (LL).

Khanh D. Vu, MD, Julie C. Hubbard, MSN, BSN, E. Lin, MS, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Susan M. O’Brien, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD

Blood (2007) 110 (11): 4338.

https://doi.org/10.1182/blood.V110.11.4338.4338

Published: 2007

Journal Articles

Survival Is Poorer in Patients with Secondary Core Binding Factor Acute Myelogenous Leukemia Compared with De Novo Core Binding Factor Leukemia.

Gautam Borthakur, MD, Nitin Jain, Hagop Kantarjian, MD, E. Lin, MS, Farhad Ravandi, MD, Sherry Pierce, RN, Elihu Estey, MD

Blood (2007) 110 (11): 2856.

https://doi.org/10.1182/blood.V110.11.2856.2856

Published: 2007

Journal Articles

CpG Island Methylation Is a Poor Prognostic Factors in Myelodysplastic Syndrome Patients and Is Reversed by Decitabine Therapy-Results of a Phase III Randomized Study.

Lanlan Shen, MD, PhD, Hagop Kantarjian, MD, Hussain Saba, MD, E. Lin, Don Berry, Saira Ahmed, Jaroslav Jelinek, MD, Jean-Pierre J. Issa, MD

Blood (2005) 106 (11): 790.

https://doi.org/10.1182/blood.V106.11.790.790

Published: 2005

NARROW

TET2 -mutant clonal hematopoiesis and risk of gout

The Association between Clonal Hematopoiesis and Gout

Experimental Modeling of Acute- and Chronic-GvHD By Xenotransplanting Human Donor PBMCs or Cord Blood CD34 + Cells (HSC) into NSG Mice

Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant

A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation

Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study.

Outcomes of Salvage Treatment in Patients with Acute Myeloid Leukemia (AML) with FLT3 Mutations.

A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.

Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL).

Chromosome 17 Abnormalities Are Associated with Worse Overall and Relapse Free Survival in Patients with Acute Myelogenous Leukemia and Poor-Risk Cytogenetics.

Venothromboembolism (VTE) in Patients (pts) with Acute Lymphocytic Leukemia (ALL), Burkitt’s Leukemia/Lymphoma (BL) or Lymphoblastic Lymphoma (LL).

Survival Is Poorer in Patients with Secondary Core Binding Factor Acute Myelogenous Leukemia Compared with De Novo Core Binding Factor Leukemia.

CpG Island Methylation Is a Poor Prognostic Factors in Myelodysplastic Syndrome Patients and Is Reversed by Decitabine Therapy-Results of a Phase III Randomized Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only